Targeted In Vivo Labeling of Receptors for Vascular Endothelial Growth Factor
暂无分享,去创建一个
William R. Wagner | Flordeliza S. Villanueva | Alexander L. Klibanov | J. Abraham | W. Wagner | A. Klibanov | F. Villanueva | G. Brandenburger | G. Schreiner | George F. Schreiner | Erxiong Lu | David Fischer | U. Schellenberger | Gary H. Brandenburger | Judith A. Abraham | Ute Schellenberger | Steven R. Woulfe | Melissa M. Csikari | E. Lu | S. Woulfe | D. Fischer
[1] T. Visser,et al. 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo. , 1998, Nuclear medicine and biology.
[2] Henry,et al. Review of Preclinical and Clinical Results with Vascular Endothelial Growth Factors for Therapeutic Angiogenesis. , 2000, Current interventional cardiology reports.
[3] F. Giordano. Angiogenesis: mechanisms, modulation, and targeted imaging. , 1999, Journal of Nuclear Cardiology.
[4] R. Jue,et al. Cysteine 116 participates in intermolecular bonding of the human VEGF(121) homodimer. , 2002, Archives of biochemistry and biophysics.
[5] D. McConnell,et al. Noninvasive Assessment of Lipid Disposition in Treated and Untreated Atherosclerotic Rabbits , 1989, Pharmaceutical Research.
[6] M Schwaiger,et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] L. Aiello,et al. Comparative Analysis of Vascular Endothelial Growth Factor Receptors on Retinal and Aortic Vascular Endothelial Cells , 1995, Diabetes.
[8] L. Brown,et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. , 1996, The American journal of physiology.
[9] N. Voelkel,et al. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. , 1995, The Journal of clinical investigation.
[10] F. Blankenberg,et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection , 2001, Nature Medicine.
[11] F Khorasheh,et al. Application of direct search optimization for pharmacokinetic parameter estimation. , 1999, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[12] Henry Td,et al. Review of Preclinical and Clinical Results with Vascular Endothelial Growth Factors for Therapeutic Angiogenesis. , 2000 .
[13] C. Ng,et al. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia. , 1995, Circulation.
[14] K. Lachapelle,et al. A persistent hindlimb ischemia model in the rabbit. , 1994, Journal of investigative surgery : the official journal of the Academy of Surgical Research.
[15] J. Isner,et al. Therapeutic Angiogenesis for Coronary Artery Disease , 2002, Annals of Internal Medicine.
[16] J. Abraham,et al. Myocardial Contrast Echocardiography Can Be Used to Assess the Microvascular Response to Vascular Endothelial Growth Factor-121 , 2002, Circulation.
[17] B. Keyt,et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. , 1996, The Journal of clinical investigation.
[18] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[19] B Z Levi,et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells , 1995, The Journal of Biological Chemistry.
[20] F. Clubb,et al. Major histocompatibility complex class II antigen expression in rejecting cardiac allografts: detection using in vivo imaging with radiolabeled monoclonal antibody. , 1997, Circulation.
[21] A. Sinusas. The potential for myocardial imaging with hypoxia markers. , 1999, Seminars in nuclear medicine.
[22] J. Narula,et al. Noninvasive detection of atherosclerotic lesions by 99mTc-based immunoscintigraphic targeting of proliferating smooth muscle cells. , 1997, Chest.
[23] A. Fischman,et al. Rapid noninvasive detection of experimental atherosclerotic lesions with novel 99mTc-labeled diadenosine tetraphosphates. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] R. Lees,et al. External Imaging of Atherosclerosis in Rabbits Using an 123I‐Labeled Synthetic Peptide Fragment , 1993, Journal of clinical pharmacology.
[25] T. Mulnix,et al. Myocardial kinetics of a putative hypoxic tissue marker, 99mTc-labeled nitroimidazole (BMS-181321), after regional ischemia and reperfusion. , 1995, Circulation.
[26] J. Witztum,et al. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[27] S J Goldsmith,et al. Receptor imaging: competitive or complementary to antibody imaging? , 1997, Seminars in nuclear medicine.
[28] F. Sheehan,et al. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. , 1986, Circulation.
[29] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[30] Matthew A. Williams,et al. Synthesis of enantiomerically pure diethylenetriaminepentaacetic acid analogs. L-Phenylalanine as the educt for substitution at the central acetic acid , 1993 .